sodium iodate

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属含氧阴离子化合物
• 英文名称: sodium iodate
• 英文别名: sodium periodate；sodium;iodate
• 化学式: IO₃*Na
• 分子量: 197.892
• InChiKey: WTCBONOLBHEDIL-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -9.56
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  3

ADMET

毒理性

• 相互作用

尽管其他氧化剂通常没有证明具有视网膜毒性，但已经显示出眼睛中碘酸盐的有害作用可以被氧化剂高锰酸钾增强，并被还原剂半胱氨酸所拮抗，但通过施用抗坏血酸（维生素C）则不会。 /碘酸盐/

ALTHOUGH OTHER OXIDIZING AGENTS HAVE NOT GENERALLY PROVED RETINOTOXIC, IT HAS BEEN SHOWN THAT INJURIOUS EFFECT OF IODATE IN EYE IS POTENTIZED BY OXIDIZING AGENT POTASSIUM PERMANGANATE, AND ANTAGONIZED BY REDUCING AGENT CYSTEINE, BUT NOT BY ADMINISTERING ASCORBIC ACID. /IODATE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

...PT...给定的SEPTOJOD IV或IP...在24小时内视力明显下降...发展为视网膜色素上皮层的扰动...大多数患者视力最终有所改善...但在大多数情况下，中心暗点...或视野缩小持续存在.../SEPTOJOD/中的碘酸盐...导致眼部损伤。/碘酸盐/

...PT...GIVEN SEPTOJOD IV OR IP...HAD MARKED REDUCTION OF VISION WITHIN 24 HR. ...DEVELOPED DISTURBANCE OF RETINAL PIGMENT EPITHELIUM... IN MOST PT VISION EVENTUALLY IMPROVED...BUT IN MAJORITY CENTRAL SCOTOMA...OR CONSTRICTION OF VISUAL FIELDS PERSISTED... IODATE IN /SEPTOJOD/...RESPONSIBLE FOR OCULAR INJURIES. /IODATE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

长期使用碘制剂可能会导致碘中毒。症状包括鼻黏膜炎、流泪、皮肤瘙痒、皮疹以及食欲不振。偶尔也会出现格雷夫斯病的症状，如心悸、震颤、出汗和体重减轻。/碘制剂/

PROLONGED USE OF IODINE PREPARATIONS...MAY LEAD TO IODISM. SYMPTOMS INCLUDE NASAL CATARRH, LACHRYMATION, SCRUFFINESS, SKIN RASHES...& LOSS OF APPETITE. OCCASIONALLY SYMPTOMS OF GRAVES' DISEASE ARE SEEN...PALPITATION OF HEART, TREMORS, SWEATING, & LOSS OF WT... /IODINE PREPN/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验表明.../碘酸盐盐类/具有氯酸盐和溴酸盐的肾毒性和溶血潜力。在禁食的狗中，定期大剂量口服通常会产生呕吐反应... /溴酸盐/

...ANIMAL EXPT SUGGEST THAT.../IODATE SALTS/ SHARE NEPHROTOXIC & HEMOLYTIC POTENTIAL OF CHLORATE & BROMATE. LARGE DOSES BY MOUTH REGULARLY PRODUCED EMESIS IN FASTED DOGS... /BROMATE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

非特异性脂肪变性在内脏中被观察到，同时肝脏、肾脏、胃肠道粘膜和膀胱出现了坏死性病变。在经口给予大量碘酸盐盐的禁食犬中，也发生了不可逆的视网膜变性。/溴酸盐/

NONSPECIFIC FATTY CHANGES WERE NOTED IN VISCERA, TOGETHER WITH NECROTIC LESIONS IN LIVER, KIDNEY, GI MUCOSA & URINARY BLADDER. IRREVERSIBLE RETINAL DEGENERATION ALSO OCCURRED /AMONG FASTED DOGS GIVEN LARGE DOSES OF IODATE SALTS BY MOUTH/. /BROMATE/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

当碘酸(131)I静脉给药时，标记的碘在兔子的房水和玻璃体中迅速传递。残留在血液中的碘酸可持续数小时，并逐渐被肝脏还原为碘化物。/碘酸/

WHEN IODATE (131)I HAS BEEN GIVEN INTRAVENOUSLY, LABELED IODINE HAS BEEN FOUND TO PASS RAPIDLY INTO AQUEOUS & VITREOUS HUMORS IN RABBITS. THAT REMAINING IN BLOOD PERSISTS FOR MANY HOURS & IS GRADUALLY REDUCED BY THE LIVER TO IODIDE. /IODATE/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在单次静脉注射几分钟后，兔玻璃体中钠、碘和硫脲的渗透速率显著增加，最大效果在30-60分钟内达到。血-玻璃体屏障通透性改变的模式证实了仅对睫状体进行攻击的想法。

WITHIN FEW MIN AFTER SINGLE IV DOSE THERE WAS MARKED INCR IN RATE OF PENETRATION OF SODIUM, IODINE & THIOUREA INTO VITREOUS BODY OF RABBIT, MAX EFFECT REACHED WITHIN 30-60 MIN. PATTERN OF ALTERED PERMEABILITY OF BLOOD-VITREAL BARRIER CONFIRMED IDEA OF EXCLUSIVE ATTACK ON CILIARY BODY.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

实验：通过每天注射30毫克/公斤，诱导兔视网膜变性。在2-24小时内，视网膜外层出现强烈的荧光素着色。在1-3周内，尽管几乎所有的视觉细胞已经消失，荧光素进入视网膜的量逐渐减少。

EXPT RETINAL DEGENERATION INDUCED IN RABBITS BY DAILY INJECTIONS OF 30 MG/KG. IN 2-24 HR INTENSE FLUORESCEIN COLORATION APPEARED IN OUTER PART OF RETINA. IN 1-3 WK FLUORESCEIN PASSAGE INTO RETINA GRADUALLY DECR ALTHOUGH THE ALMOST VISUAL CELLS HAD DISAPPEARED.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

眼组织及体液中碘酸盐的积累可能是碘酸盐视网膜毒性的解释，研究者通过静脉注射NaIO3（30毫克/千克）进行了研究。碘酸盐的效果不是由于眼组织中碘酸根的积累，而是由于对还原为I-的生物化学机制造成的损害。

ACCUM OF IODATE IN EYE TISSUES & FLUIDS AS POSSIBLE EXPLANATION OF RETINOTOXIC EFFECT OF IODATE WAS STUDIED BY IV INJECTION OF NAIO3 (30 MG/KG). EFFECT OF IODATE IS NOT DUE TO ACCUM OF IO3 IN EYE TISSUE, BUT TO DAMAGE TO BIOCHEM MECHANISMS INVOLVED IN REDN TO I-.

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  sodium iodate 在 Al or Zn 作用下， 以 sodium hydroxide 为溶剂， 生成 sodium iodide
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Na: SVol.1, 24, page 150 - 152

  摘要：

  DOI：
• 作为产物：
  描述：

  sodium periodate 以 neat (no solvent) 为溶剂， 生成 sodium iodate
  参考文献：
  名称：

  KIO 4和NaIO 4的热分解与固态同位素交换反应的关系

  摘要：

  已经研究了KIO 4和NaIO 4的热分解。分解产物KIO 3或NaIO 3，在加热期间，Al 2 O 3经历非常有效的扩散，使得部分分解的晶体由两部分组成：外部是几乎纯碘酸盐的易碎层，而内部是几乎纯高碘酸盐的固体晶格。后者的尺寸不受分解的影响，因此其密度与分解的分数成比例地降低。分解等温线在较长的加热时间内呈现出饱和，这不是由于大气效应引起的，而是在连续去除外层的情况下进行加热时受到抑制。数据的动力学分析表明，在较低温度下发生的交换过程与分解之间具有显着的连续性。特别是反应的维数，n根据Erofeev方程，在KIO 4中，温度升高时，KIO 4的范围大致为1至2，在后者情况中，其范围为2至3。这些值在NaIO 4中被系统地提高了一个单位，这表明产生驱动缺陷的成核过程不能像KIO 4那样被忽略。交换和分解都是由某些空位组合缺陷的扩散引起的，这促进了碘酸盐的扩散，并最终触发了分解。在足够高的

  DOI：

  10.1039/f19888402831
• 作为试剂：
  描述：

  对羟基苯甘氨酸 在 sodium iodate 、 硫酸 、 碘 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxy-3-iodophenyl)acetic acid
  参考文献：
  名称：

  10.1021/acs.jmedchem.4c00673

  摘要：

  DOI：

  10.1021/acs.jmedchem.4c00673

文献信息

• Compounds useful as phosphotyrosine mimics
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US06156784A1

  公开（公告）日：2000-12-05

  Disclosed are compositions containing compounds of the formula (I) below wherein A,B,C,G,Q and R are defined herein. The compounds are useful as phosphotyrosine mimics that, when incorporated into an appropriate molecular structure, inhibit the binding of tyrosine kinase-dependent regulatory proteins to their native phosphotyrosine-containing ligands or receptors. Also disclosed are methods for preparing the compounds of the formula (I). ##STR1##

  披露了含有以下式（I）化合物的组合物，其中A、B、C、G、Q和R在此定义。这些化合物可用作磷酸酪氨酸模拟物，当它们被纳入适当的分子结构中时，能抑制酪氨酸激酶依赖的调节蛋白与其天然磷酸酪氨酸含有的配体或受体的结合。还披露了制备式（I）化合物的方法。
• 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
  申请人：Novartis AG

  公开号：US06080743A1

  公开（公告）日：2000-06-27

  2,3-Dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives of formula (I), ##STR1## wherein one of the radicals R.sub.1, and R.sub.2 is a group R.sub.5 and the other is a group of formula --CH(R.sub.6)--alk--R.sub.7 (Ia), --alk--CH(R.sub.6 -R.sub.7 (Ib), --alk--N(R.sub.8)--X--R.sub.7 (Ic), --alk--N.sup.+ (R.sub.8)(R.sup.9)--X--R.sub.7 A.sup.- (Id), --alk--O--X--R.sub.7 (Ie) or --alk--S--X--R.sub.7 (If), R.sub.3, R.sub.4 and R.sub.5 are each independently of the others hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro, R.sub.6 is unsubstituted or lower alkylated and/or lower alkanoylated amino, R.sub.7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; cyano; acyl derived from carbonic acid or from a semiester or semiamide of carbonic acid, from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or from a phosphonic acid ester; amino that is unsubtituted or aliphatically or araliphatically substituted and/or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, R.sub.8 is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic semiester of carbonic acid, or R.sub.7 and R.sub.8, together with X and the nitrogen atom bonding R.sub.8 and X, form an unsubstitued or substituted mono- or di-azaxycloalkyl, azoxacycloalkyl, azathiacycloalkyl or optionally oxidised thiacycloalkyl radical bonded via a nitrogen atom, or an unsubstituted or substituted, optionally partially hxdrogenated aryl or heteroaryl radical, R.sub.9 is an aliphatic or araliphatic radical, or R.sub.7, R.sub.8 and R.sub.9 together with X and the nitrogen atom bonding R.sub.8, R.sub.9 and X, form an unsubstituted or substituted quaternary heteroaryl radical bonded via the quaternary nitrogen atom, with A.sup.- being the anion of a protonic acid, alk is lower alkylene, and X (unless, together with R.sub.7 and R.sub.8 and the nitrogen atom bonding R.sub.8 and X or together with the nitrogen atom bonding R.sub.8, R.sub.9 and X, it forms part of one of the mentioned ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, and the pharmaceutically acceptable salts thereof can be used in the preparation of a medicament for the treatment of pathological conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor.

  公式(I)的2,3-二氧代-1,2,3,4-四氢喹啉基衍生物，其中R.sub.1和R.sub.2中的一个是R.sub.5基团，另一个是--CH(R.sub.6)--alk--R.sub.7 (Ia)、--alk--CH(R.sub.6)--R.sub.7 (Ib)、--alk--N(R.sub.8)--X--R.sub.7 (Ic)、--alk--N.sup.+ (R.sub.8)(R.sup.9)--X--R.sub.7 A.sup.- (Id)、--alk--O--X--R.sub.7 (Ie)或--alk--S--X--R.sub.7 (If)的公式基团；R.sub.3、R.sub.4和R.sub.5各自独立地是氢、低碳基、卤素、三氟甲基、氰基或硝基；R.sub.6是未取代或低碳基化和/或低脂肪酰化的氨基；R.sub.7是氢；一种脂肪、环脂或杂环脂基；氰基；从碳酸或碳酸半酯或半酰胺、硫酸或脂肪或芳香磺酸、磷酸或膦酸酯衍生的酰基；未取代或烷基或芳基取代和/或烷基、芳基或芳香酰基取代的氨基；或芳香或杂环芳基，R.sub.8是氢；一种脂肪或芳基基团；或从脂肪或芳香羧酸或从碳酸的脂肪或芳香半酯衍生的酰基，或R.sub.7和R.sub.8连同X和与R.sub.8和X连接的氮原子形成未取代或取代的单环或二环氮杂环脂、氧杂环脂、硫杂环脂或可选择氧化的硫杂环脂基，通过氮原子连接，或未取代或取代的、可选择部分氢化的芳基或杂芳基基团，R.sub.9是一种脂肪或芳基基团，或R.sub.7、R.sub.8和R.sub.9连同X和连接R.sub.8、R.sub.9和X的氮原子形成通过季铵氮原子连接的未取代或取代的杂芳基基团，A.sup.-是质子酸的阴离子，alk是低碳烷基，X（除非与R.sub.7和R.sub.8以及连接R.sub.8和X的氮原子或与连接R.sub.8、R.sub.9和X的氮原子形成所述环系统之一的一部分）是二价的脂肪、环脂或芳基基团或直接键，其药学上可接受的盐可用于制备用于治疗对AMPA、kainate和/或甘氨酸-NMDA受体结合位点阻塞敏感的病理条件的药物。
• Lactone compounds for treating patients with precancerous lesions
  申请人：Cell Pathways, Inc.

  公开号：US05696159A1

  公开（公告）日：1997-12-09

  Substituted lactone compounds are useful in the treatment of precancerous lesions.

  替代内酯化合物在治疗癌前病变方面具有用处。
• Lactone compounds for treating patient with precancerous lesions
  申请人：Cell Pathways, Inc.

  公开号：US05776962A1

  公开（公告）日：1998-07-07

  Substituted lactone compounds are useful in the treatment of precancerous lesions and neoplasms.

  替代内酯化合物在治疗癌前病变和肿瘤中是有用的。
• Organometallic Iridium Complex Containing a Dianionic, Tridentate, Mixed Organic–Inorganic Ligand
  作者：Aaron J. Bloomfield、Adam J. Matula、Brandon Q. Mercado、Victor S. Batista、Robert H. Crabtree

  DOI：10.1021/acs.inorgchem.6b01218

  日期：2016.8.15

  A pentamethylcyclopentadienyl–iridium complex containing a tricyclic, dianionic, tridentate, scorpionate (facial binding), mixed organic–inorganic ligand was synthesized and characterized by single-crystal X-ray crystallography, as well as polynuclear NMR, UV–vis, and IR spectroscopies. The central cycle of the tridentate ligand consists of a modified boroxine in which two of the boron centers are

  合成了一种五甲基环戊二烯基-铱配合物，该配合物包含三环，双阴离子，三齿，蝎子（表面结合），混合的有机-无机配体，并通过单晶X射线晶体学，多核NMR，UV和IR光谱进行了表征。 。三齿配体的中心循环由修饰的环硼氧烷组成，其中两个硼中心是四面体阴离子硼酸酯。该络合物在25°C下可在水溶液中稳定水解> 9周，但可在12 s内与50 mM高碘酸钠溶液反应形成高碘酸盐驱动的析氧催化剂，其周转频率> 15 s –1。但是，催化剂在5分钟内几乎完全失活，平均循环次数约为。每个铱原子有2500个氧分子。在此时间范围内未观察到纳米颗粒，但在这些实验条件下催化剂活化后4小时内形成纳米颗粒。母体复合物是使用密度泛函理论建模的，该理论准确反映了复合物的几何形状，并表明了以铱和硼环为中心的轨道之间的显着相互作用。

表征谱图